-

Tandem Diabetes Care Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

  • Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Thursday, March 2, 2023 at 2:45pm ET (11:45am PT),
  • Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 12:50pm ET (9:50am PT),
  • Raymond James & Associates’ 44th Annual Institutional Investors Conference on Wednesday, March 8, 2023 at 9:50am ET (6:50am PT),
  • Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 8:40am ET (5:40am PT), and
  • Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 11:15am ET (8:15am PT).

The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Industry:

Tandem Diabetes Care, Inc.

NASDAQ:TNDM
Release Versions
English
$Cashtags
$TNDM
Hashtags
#TNDM

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
Tandem Diabetes Care/Facebook
Tandem Diabetes Care/LinkedIn
Tandem Diabetes Care/Twitter
More News From Tandem Diabetes Care, Inc.

Tandem Mobi Now Compatible with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. "By expanding to Android, we’re broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief...

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a...

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S...
Back to Newsroom